Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva ...

The drug is being jointly developed and commercialised through a partnership between Lundbeck and Otsuka. Credit: Longfin Media/Shutterstock. The European Commission (EC) has approved Otsuka ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Cabenuva is indicated as a complete regimen for the treatment ... ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to ...

That equation led Vyvgart, argenx’s treatment for generalized myasthenia gravis (gMG), to take the top spot, with an overall score of 3.9. Cabenuva, GSK’s long-acting HIV treatment ...

About Cabenuva (cabotegravir + rilpivirine ... is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and ... physician experience we have with Cabenuva and pioneering the next generation ...

About Cabenuva (cabotegravir + rilpivirine ... About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated ...